Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy

• Published in: Drugs (New York, N.Y.) N.Y.), 2023-11, Vol.83 (16), p.1475-1499
• Main Authors: Rajasekaran, Arun, Green, Todd J., Renfrow, Matthew B., Julian, Bruce A., Novak, Jan, Rizk, Dana V.
• Format: Article
• Language: English
• Subjects: Amino acids; Antigen-antibody complexes; Biopsy; Clinical trials; Complement; Complement activation; Complement C3; Complement component C3; Complement system; Diagnosis; Glomerulonephritis; Glomerulonephritis, IGA - drug therapy; Health services; Hematuria; Humans; Hypertension; Immunofluorescence; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunoglobulins; Internal Medicine; Kidney; Kidney diseases; Kidneys; Life expectancy; Life span; Medical prognosis; Medicine; Medicine & Public Health; Microscopy; Nephropathy; Pathogenesis; Patients; Pharmacology/Toxicology; Pharmacotherapy; Proteins; Renal failure; Renal Insufficiency; Review Article; Therapeutic targets
• ISSN: 0012-6667; 1179-1950; 1179-1950
• DOI: 10.1007/s40265-023-01940-2

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a frequent cause of kidney failure. Currently, the diagnosis necessitates a kidney biopsy, with routine immunofluorescence microscopy revealing IgA as the dominant or co-dominant immunoglobulin in the glomerular immuno-deposits, often with IgG and sometimes IgM or both. Complement protein C3 is observed in most cases. IgAN leads to kidney failure in 20–40% of patients within 20 years of diagnosis and reduces average life expectancy by about 10 years. There is increasing clinical, biochemical, and genetic evidence that the complement system plays a paramount role in the pathogenesis of IgAN. The presence of C3 in the kidney immuno-deposits differentiates the diagnosis of IgAN from subclinical glomerular mesangial IgA deposition. Markers of complement activation via the lectin and alternative pathways in kidney-biopsy specimens are associated with disease activity and are predictive of poor outcome. Levels of select complement proteins in the circulation have also been assessed in patients with IgAN and found to be of prognostic value. Ongoing genetic studies have identified at least 30 loci associated with IgAN. Genes within some of these loci encode complement-system regulating proteins that can interact with immune complexes. The growing appreciation for the central role of complement components in IgAN pathogenesis highlighted these pathways as potential treatment targets and sparked great interest in pharmacological agents targeting the complement cascade for the treatment of IgAN, as evidenced by the plethora of ongoing clinical trials.